It refers to the long-term release drug composition (LAP) of parents, including the carboxamide of compound 6 - (n - (7-chloro-1-hydroxy-1,3-dihydrobenzo [C] [1,2] oxaborol-5-il) methylsulfonamide-5-cyclopropene-2 - (4-fluorophenyl) - n-methylbenzofuran-3-formula I, which is combined with a compound IIA or IIB, Where R is an anti Mir 122 at 5 '- 3' and ring a is bike or non bike. In addition, it also includes a surface active system, including a surface active substance, such as polyoxyethylene fatty acid esters, polyoxameros, etc.； a stabilizer, such as polyethylene glycol, carbohydrate calcium,And a cotton salt This drug synthesis is useful in the treatment of hepatitis C virus (VHC) infection.Se refiere a una composicion farmaceutica parenteral de liberacion prolongada (LAP) que comprende al compuesto 6-(N-(7-cloro-1-hidroxi-1,3-dihidrobenzo[c][1,2]oxaborol-5-il)metilsulfonamido-5-ciclopropil-2-(4-fluorofenil)-N-metilbenzofuran-3-carboxamida de formula I en combinacion con un compuesto de formulas IIA o IIB, donde R es un oligonucleotido anti-miR-122 en 5'-3' y el anillo A es cicloalquilo o heterociclilo. Ademas, comprende un sistema tensioactivo que comprende un tensioactivo tal como esteres de acidos grasos de polioxietileno sorbitan, poloxameros, entre otros； un estabilizador tal como polietilenglicoles, carboximetilcelulosa de calcio, entre otros y una sal tamponadora. Dicha composicion farmaceutica es util en el tratamiento de infecciones causadas por el virus de la hepatitis C (VHC)
